greeksoup/ stock research
Stock research / United States / TAK / Year to 31 March 2023

Takeda Pharmaceutical Company Limited (TAK) annual results, year to 31 March 2023: revenue JPY 4,027 billion, from the 20-F

Takeda Pharmaceutical Company Limited files a 20-F with the SEC once a year, in yen. In the year to 31 March 2023 it reported revenue of JPY 4,027 billion ($29.8 billion at the year's average rate), up 12.8% on the year before. Its profit attributable to shareholders was JPY 317 billion, up 37.8%, and diluted earnings per share JPY 201.94.

Revenue
JPY 4,027 billion
+12.8% on the year
FY2017FY2023
Operating margin
12.2%
12.9% a year earlier
FY2017FY2023
Net income
JPY 317 billion
+37.8% on the year
FY2017FY2023
Diluted EPS
JPY 201.94
+38.4% on the year
FY2017FY2023

this yearthe year beforeIn yen as filed. Hover a bar for its figure.

Income statement (profit and loss)

Year toMar 2022Mar 2023
Revenue3,5694,027
Cost of sales1,1071,244
Research and development526633
Operating profit461491
Finance costs167170
Profit before tax303375
Income tax72.458.1
Profit for the year230317
Profit attributable to shareholders230317
Filing20-F20-F
JPY billion, from the 20-F on the SEC's EDGAR, linked in the last row, on the IFRS tags the company filed.
Read moreA line the company does not file under the standard tag is left out rather than estimated.
Year toMar 2022Mar 2023
Diluted EPS145.87201.94
Basic EPS147.14204.29
Filing20-F20-F

JPY per ordinary share, as filed.

Cash flow

Year toMar 2022Mar 2023
Cash from operations1,123977
Purchase of property, plant and equipment123141
Free cash flow1,000836
Cash from investing-198-607
Cash from financing-1,070-709
Depreciation and amortisation583664
Buybacks77.526.9
Dividends paid284279
Filing20-F20-F

JPY billion. Free cash flow is cash from operations less the purchase of property, plant and equipment, arithmetic on the two filed lines.

Balance sheet

Year toMar 2022Mar 2023
Funded by
Equity attributable to shareholders5,6836,354
Non-controlling interests0.50.5
Borrowings, as filed4,3454,382
Lease liabilities465479
Other liabilities2,6842,741
Total equity and liabilities13,17813,958
Owned
Property, plant and equipment1,5831,691
Goodwill4,4084,791
Other intangible assets3,8194,270
Cash and cash equivalents850534
Trade and other receivables697649
Inventories853986
Other assets9691,037
Total assets13,17813,958
Filing20-F20-F

JPY billion, at each fiscal year end.

Ratios on the filed lines

Year toMar 2022Mar 2023
Operating margin12.9%12.2%
Net margin6.4%7.9%
Free cash flow margin28.0%20.8%
Return on year-end equity4.0%5.0%
Effective tax rate23.9%15.5%
Filing20-F20-F

Arithmetic on the filed lines of the same year.

20-F for the year to 31 March 2023, filed 25 June 2025: the filing. The figures are in yen as filed.